Press release
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential
About this update from Eton Pharmaceuticals, Inc.
[{"type":"text","content":"Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of product candidate ET-700Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2025. “The first quarter was another exceptional quarter for Eton. We reported record financial results, launched two recently acquired commercial products, and achieved critical milestones with the advancement of our development pipeline. In its first quarter of relaunch, INCRELEX is already tracking ahead of our expectations, with a significant number of new patients added to therapy in the first quarter, and we are confident that it has a long runway for growth in the years ahead. In March, we relaunched GALZIN with our full Eton Cares patient support program to a strong reception in the Wilson disease community. As part of our commitment to investing in Wilson disease, we also announced our ET-700 development program, which we believe has the potential to drastically improve the lives of Wilson disease patients.” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We are now less than one month away from a potential launch of ET-400. We have been actively engaged with the FDA as part of the ongoing review, and we remain prepared to launch quickly upon potential approval on its Prescription Drug User Fee Act (PDUFA) date of May 28th. With three expected product launches this year and several late-stage candidates progressing in development, 2025 is shaping up to be another monumental year for E...